VACCINE COMBINING MULTIPLE CLASS I PEPTIDES AND MONTANIDE ISA 51VG WITH ESCALATING DOSES OF ANTI-PD-1 ANTIBODY NIVOLUMAB OR IPILIMUMAB WITH NIVOLUMAB FOR PATIENTS WITH RESECTED STAGES IIIC/ IV MELANOMA: